

ATTORNEY DOCKET NO: UBC.P-020-2 PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Gleave et al.

US Application No.: 09/944,326

Filing Date:

August 10, 2001

For:

TRPM-2 Antisense Therapy

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents Washington, DC 20231

Sir:

Applicant requests that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent and Trademark Office file relating to the above-captioned application. Also, see the enclosed copy of the PCT International Search Report dated August 11, 2000. Copies of the references are enclosed for the Examiner's convenience.

No fee is believed to be due with this paper as we have not received an action on the merits.

Respectfully submitted,

OPPEDAHL & LARSON LLP

Marina I Laros

Marina T. Larson, Ph.D.

Reg. No. 32,038


P.O. Box 5068

Dillon, Co. 80435-5068

970-468-6600

I hereby certify that this paper and the attachments named herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on_ NOV. 30.2001

Date of Signature



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 09/944,326 Applicant: Gleave et al

Filing Date: August 10, 2001 Title: TRPM-2 Antisense Therapy Attorney Docket No.: UBC.P-020-2

Page 1 of 2

U.S. PATENT DOCUMENTS


Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

FOREIGN PATENT DOCUMENTS

Patent No.	Name of Persons or applicant	Date of Publication of Cited Document

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials			
•	Buttyan et al., "Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death" <i>Molecular and Cellular Biology</i> Aug. 1989, Vol. 9, No. 8, pp. 3473-3481		
•	Millar et al., "Localization of mRNAs by in-situ hybridization to the residual body at stages IX-X of the cycle of the rat seminiferous epithelium: fact or artefact?" <i>International Journal of Andrology</i> , 17:149-160		
r	Darby et al., "Vascular Expression of Clusterin in Experimental Cyclosporine Nephrotoxicity" <i>Exp Nephrol</i> 1995; 3:234-239		
•	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays" <i>Nature Biotechnology</i> Volume 15, June 1997, pp. 537-541		
•	Sensibar et al., "Prevention of Cell Death Induced by Tumor Necrosis Factor alpha in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin)," Cancer Research. June 1, 1995, Vol. 55, pp. 2431-2437		
•	Miyake et al., "Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer", Cancer Research 60, January 1, 2000, pp. 170-176		
`	Yang et al., "Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death", <i>Proc. Nat'l. Acad. Sci. USA</i> , Vol. 97, Issue 11, pp 5907-5912, May 23, 2000		
`	Benner, et al., "Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies", Journal of Pharmacological and Toxicological Method, 37:229-235 (1997)		



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 09/913,325 Applicant: Gleave et al

Filing Date: August 10, 2001 Title: TRPM-2 Antisense Therapy

Attorney Docket No.: UBC.P-020

Page 2 of 2

	Kadomatsu, et al, "Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle", <i>Cancer Res</i> April 1, 1993, 53(7):1480-1483		
	Kyprianou, et al., "bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells.", <i>Int J Cancer</i> , Jan. 27, 1997, 70(3):341-348		
Wright, et al., "A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TF levels in human prostate tumor xenografts.", Exp Cell Res, Jan. 10, 1996, 222(1):54-60			
	Bruchovsky, et al., "Control of tumor progression by maintenance of apoptosis.", Prostate Suppl., 1996, 6:13-21		

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner	Signature	Date Considered